Cooper Companies Raises Free Cash Flow Guidance, Secures US and European Lens Contracts
In Q4 2025, Cooper Companies eased supply constraints for premium silicone hydrogel lenses and won new private-label contracts in the US and Europe. The firm raised long-term free cash flow guidance, tied executive pay to shareholder return and free cash flow, and its shares closed at $81.48.
1. Q4 Operational Improvements
In the fourth quarter of 2025, Cooper Companies alleviated supply constraints on its premium daily silicone hydrogel contact lenses and secured new private-label manufacturing agreements in both the US and European markets. The CooperSurgical segment also reported sequential revenue improvement in the Asia Pacific region, driven by stronger procedure volumes despite broader macroeconomic headwinds.
2. Guidance and Compensation Changes
The company raised its long-term free cash flow guidance, reflecting confidence in cash generation from its expanded product platforms. Management compensation metrics were revised to include total shareholder return and free cash flow targets, aligning executive incentives more closely with shareholder value creation.
3. Strategic Review and Board Addition
Cooper Companies announced a strategic review of its women’s health business, signaling potential divestiture or restructuring to enhance focus on core franchises. The board was bolstered by the addition of Steris CEO Emeritus Walter Rosebrough, bringing deep medical device and operational expertise to support long-term growth.
4. Stock Performance Metrics
On February 9, 2026, shares of Cooper Companies closed at $81.48, reflecting a one-month decline of 0.27% and a 52-week loss of 12.81%. The company’s market capitalization stood at $16.2 billion, with analyst attention focused on the impact of recent operational gains and financial guidance updates.